“…Accordingly, D3R has gained attention as a clinical target for treatment of addiction-related behavior (Ashby et al, 2015a; Ashok et al, 2017; Maramai et al, 2016; Sokoloff and Le Foll, 2017). Blockade of D3R has been shown to inhibit psychostimulant and opiate self-administration (Xi et al, 2005; You et al, 2019), conditioned place preference (CPP) to drugs of abuse (Xi et al, 2006), and reinstatement of drug-seeking behavior and CPP triggered by stress (Guerrero-Bautista et al, 2019; Xi et al, 2004).…”